Leukemia stem cells (LSCs) pose a significant challenge in treating acute myeloid leukemia (AML) due to their resistance to ...

A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Transplant or no transplant for TP53 ...

The following is a summary of “Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation ...

Sophie Patnicroft Gray received a stem cell transplant after she was diagnosed in 2019 with acute myeloid leukaemia. Source: Supplied / Leukaemia Foundation of Australia More than 140,000 people ...

BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

But leukemic stem cells can hide from TKIs in a patient's ... for patients with chronic myeloid leukemia (CML) with molecular evidence of disease (SWOG trial S1712).

During haematopoiesis, stem cells can differentiate into either myeloid-lineage cells — such as red blood cells, megakaryocytes (cells that form platelets) and cells of the innate immune system ...

A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic ...

A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.